论文部分内容阅读
目的探讨养肝消瘤汤联合替吉奥胶囊、奥沙利铂(0XA)治疗晚期原发性肝癌的疗效。方法将2008年6月—2012年6月收治的68例患者分为两组,治疗组40例晚期原发性肝癌患者,第1天接受奥沙利铂130 mg/m2静脉滴注;第1~14天替吉奥胶囊80 mg/(m2·d),分2次口服。并配合口服养肝消瘤汤,3周为1个周期。对照组28例采用保肝及对症处理。结果治疗组PR 12例(30%),NC 20例(41%),PD 8例(20%);对照组PR 2例(7%),NC 6例(21%),PD 20例(72%),(P<0.05),治疗组生存期为平均9.2个月,对照组平均2.4个月,治疗组AFP下降(P<0.01),肿瘤明显缩小,而对照组无明显变化。不良反应主要为粒细胞减少40%(16/40),血红蛋白减少20%(8/40),血小板减少22%(9/40)和较轻的神经毒性17%(7/40),。结论养肝消瘤汤联合替吉奥胶囊、奥沙利铂方案治疗晚期原发性肝癌有效,值得临床进一步研究。
Objective To investigate the therapeutic effect of Yanggan Xiaolu Decoction combined with Tigao capsule and oxaliplatin (0XA) in the treatment of advanced primary liver cancer. Methods Sixty-eight patients admitted to our hospital from June 2008 to June 2012 were divided into two groups. Forty patients with advanced primary hepatocellular carcinoma in the treatment group received intravenous infusion of oxaliplatin 130 mg / m 2 on day 1; ~ 14 days for Geo capsule 80 mg / (m2 · d), 2 times orally. And with oral Liver Liver tumor soup, 3 weeks for a cycle. Control group, 28 cases of liver and symptomatic treatment. Results PR 12 cases (30%), NC 20 cases (41%) and PD 8 cases (20%) in the treatment group, 2 cases in the control group (7% %) (P <0.05). The survival time was 9.2 months in the treatment group and 2.4 months in the control group. The AFP in the treatment group was decreased (P <0.01), the tumor size was significantly reduced, and the control group had no significant change. Adverse reactions were mainly 40% (16/40) of neutropenia, 20% (8/40) reduction of hemoglobin, 22% (9/40) of thrombocytopenia and 17% (7/40) of mild neurotoxicity. Conclusions Yangganxiaojie Decoction combined with Tigao capsule, oxaliplatin regimen in the treatment of advanced primary liver cancer is worthy of clinical further study.